Biotie Therapies - Company Announcement

Biotie's Stock Exchange Releases published in 2010

BIOTIE THERAPIES CORP.     STOCK EXCHANGE ANNOUNCEMENT 25 March 2011 at 9.15
a.m.

Biotie's Stock Exchange Releases published in 2010
The following list includes all Biotie Therapies Corp.'s Stock Exchange Releases
and Stock Exchange Announcements published in 2010.
Stock Exchange Releases, Stock Exchange Announcements and Press Releases
published by Biotie are available on the company's web site
athttp://www.biotie.com/In_English/Investors/Stock_Exchange_Releases
January
13.01.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act relating to decrease in holdings
19.01.
Biotie reports positive top-line data from clinical study with VAP-1 antibody in
rheumatoid arthritis patients - BTT-1023 is well tolerated and shows signals of
therapeutic activity

February

23.02.
Biotie will publish its Financial Statement Release for 1 January - 31 December
2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish time

26.02.
Biotie Therapies Corp. financial statement release January 1 - December 31, 2009

March

09.03.
Biotie Provides Update on Pfizer Research Collaboration

10.03.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act relating to decrease in holdings

15.03.
Biotie's Annual Report 2009 and Corporate Governance Statement have been
published

15.03
Biotie's Stock Exchange Releases published in 2009

17.03.
Invitation to The Annual General Meeting of Biotie Therapies Corp.

April

07.04.
Revised proposal from the Board's Nomination and Remuneration Committee to the
Annual General Meeting of shareholders

15.04.
Resolutions of the Annual General Meeting of Biotie Therapies Corp.

22.04.
Biotie to continue development of and maintain global rights to BTT-1023, its
novel VAP-1 antibody for inflammatory disease

26.04.
Biotie reports positive top-line data from clinical study with its third
generation oral PDE4 inhibitor - ELB353 is well tolerated and shows clear
pharmacological activity

May

07.05.
Biotie Therapies interim report: January - March 2010

August

06.08.
Biotie Therapies interim report: January - June 2010

11.08.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

26.08.
Directed issue of shares in Biotie Therapies Corp. pursuant to Standby Equity
Distribution Agreement

September

14.09.
Biotie completes Phase I with VAP-1 antibody - BTT-1023 continues to demonstrate
favourable safety profile

October

15.10.
Biotie regains rights to develop PDE10 inhibitors for CNS disorders

25.10.
Correction to Biotie Therapies Corp. interim report for January - June 2010

25.10.

Biotie Therapies Corp.'s share issue to the company itself without consideration

25.10.
A prospectus concerning Biotie Therapies Corp.'s issue of shares to the company
itself without consideration has been published

26.10.
New Biotie Therapies Corp. shares registered with the trade register

29.10.
Biotie Announces Restructuring Plan; Future Focus Exclusively on Clinical
Development; Conference Call Today

29.10.
Biotie and Roche conclude research and option agreement for SSAO inhibitors

29.10.
Biotie Therapies interim report: January - September 30, 2010

November

22.11.2010
Directed offer of treasury shares in Biotie Therapies Corp. pursuant to Standby
Equity Distribution Agreement

December

03.12.
Share capital increase registered with the trade register

08.12.
Directed offer of treasury shares in Biotie Therapies Corp. pursuant to Standby
Equity Distribution Agreement

22.12.
Biotie's employee co-determination process concluded - restructuring complete

30.12.
Biotie's Financial Information in 2011

Turku, March 25, 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com
Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

Biotie Therapies Corp.

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, bipolar disorder, addictions
and drug dependence) and inflammatory diseases (rheumatoid arthritis, psoriasis,
chronic obstructive pulmonary disease and others).

It has several innovative small molecule and biological drug candidates at
different stages of clinical development. Biotie's products address diseases
with high unmet medical need and significant market potential.

Some of the programmes have been validated through licensing agreements for
development and commercialization with top-tier pharmaceutical partners
including H. Lundbeck A/S, UCB Pharma S.A.and Seikagaku Corporation. The most
advanced product, nalmefene for alcohol dependence, is currently in phase III
clinical development by licensing partner H. Lundbeck A/S.

Shares are listed on NASDAQ OMX Helsinki Ltd.




[HUG#1499918]